SCHEMBL16166152

SCHEMBL16166152

FC(F)n1cc(Cl)cn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4352728 0.76
SCHEMBL2765034 0.74 PLAU (0.30)
SCHEMBL10711431 0.73
SCHEMBL25293350 0.73 ACHE (0.41)
SCHEMBL12755533 0.71
SCHEMBL22715404 0.71
SCHEMBL28663728 0.71
SCHEMBL17102326 0.71
SCHEMBL3262269 0.71
SCHEMBL22472907 0.71 ELANE (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160052920-A1 BACE1 INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2016-02-25 US claimed
EP-2984086-A1 BACE1 INHIBITORS F. Hoffmann-La Roche AG (CH) 2016-02-17 EP claimed
WO-2014166906-A1 BACE1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2014-10-16 WO claimed
US-20160052920-A1 BACE1 INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2016-02-25 US disclosed
EP-2984086-A1 BACE1 INHIBITORS F. Hoffmann-La Roche AG (CH) 2016-02-17 EP disclosed
US-20150150877-A1 NOVEL OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE NOVARTIS AG (CH) 2015-06-04 US disclosed
WO-2014166906-A1 BACE1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2014-10-16 WO disclosed